Genmab A/S (NASDAQ:GMAB - Get Rating) was downgraded by investment analysts at Citigroup from a "buy" rating to a "neutral" rating in a research report issued on Tuesday, The Fly reports.
https://www.marketbeat.com/instant-alerts/nasdaq-gmab-a-buy-or-sell-right-now-2022-12-2-3/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.